Trevi Therapeutics Secures $50 Million Underwritten Offering
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a pioneering clinical-stage biopharmaceutical company, has announced a significant underwritten offering aiming to raise $50 million. This financing will support the company’s critical initiatives, particularly the advancement of its investigational therapy, Haduvio™, designed for chronic cough treatment in patients suffering from idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Details of the Offering
The underwritten offering consists of 12,500,000 shares of Trevi’s common stock, priced at $4.00 each. This capital injection is essential for offering Trevi the resources necessary to expedite the development and eventual commercialization of Haduvio, an oral formulation of nalbuphine extended-release. The company anticipates closing this offering shortly, subject to usual closing conditions.
Investor Participation
Notably, the financing has attracted both new and existing investors, spotlighting the confidence in Trevi’s potential. Participants in this offering include prominent investment firms such as Adage Capital Partners LP, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital Management LP, and Vivo Capital, among others. This participation reflects a strong belief in Trevi’s targeted approach to addressing chronic cough conditions.
Management of the Offering
To ensure effective execution, Leerink Partners, Stifel and Oppenheimer & Co. are acting as joint book-running managers for the offering. Needham & Company takes on the lead management role, with Jones and B. Riley Securities serving as co-managers. This experienced team is crucial in managing the intricacies of the fundraising process, ensuring it aligns with Trevi’s broader strategic goals.
Compliance and Prospects
The offered shares come under a shelf registration statement filed with the Securities and Exchange Commission (SEC), which allows Trevi to efficiently raise funds while staying compliant with regulatory requirements. The registration was initially filed in late June of the previous year and has now been declared effective, paving the way for this timely offering.
About Haduvio™
Haduvio™ acts on the cough reflex arc, targeting opioid receptors like kappa agonist and mu antagonist (KAMA) which are pivotal in managing cough hypersensitivity. The therapeutic outlook is promising, as nalbuphine does not have scheduled restrictions by the U.S. Drug Enforcement Agency, broadening its accessibility for patient treatment plans.
Company Overview
Trevi Therapeutics, Inc. is dedicated to advancing clinical development focused on improving the quality of life for patients battling serious health conditions. The company’s commitment and innovative approaches have positioned it as a leader in the biopharmaceutical sector, particularly in areas with significant unmet medical needs.
As Trevi continues to develop therapies like Haduvio, it is poised to make a positive impact within the biopharmaceutical arena. The anticipated funds from the offering will be pivotal in facilitating continued research and development, with the potential for widespread benefits to patients affected by chronic cough.
Frequently Asked Questions
What is the purpose of Trevi Therapeutics' offering?
The $50 million offering aims to support the development of Haduvio™ and bolster the company's operations.
Who are the key investors in this offering?
Key investors include Adage Capital Partners LP, Frazier Life Sciences, Logos Capital, and more.
What is Haduvio™ designed to treat?
Haduvio™ is developed to treat chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
How does Haduvio™ work?
Haduvio™ works by acting on opioid receptors involved in controlling cough hypersensitivity.
What does this financing mean for Trevi’s future?
This financing provides essential resources for Trevi to accelerate research and development, enhancing its prospects in the biopharmaceutical sector.
